OBJECTIVE: Graft-versus-host disease (GVHD) is a leading cause of morbidity and mortality in patients receiving hematopoietic cell transplant. It is estimated that 40-70% of engrafted patients surviving the initial transplant eventually develop chronic GVHD (cGVHD), which can persist for months to years and require long-term management from multiple disciplines. This review describes the oral component of this transplant complication. DESIGN: The search related to GVHD patho-biology, salivary gland disease after hematopoietic cell transplant and treatments for oral GVHD encompassed literature from 1966 through 2008. Searches were limited to the MEDLINE/PubMed database and English language literature in peer-reviewed journals. RESULTS: Our understanding of the patho-biology of oral cGVHD is based on studies of other affected tissues. It is difficult to determine the prevalence and incidence of salivary gland disease after transplant because there is no universally accepted case definition. In general, clinical trials for treatment of oral cGVHD have been too small to make strong recommendations for use in clinical practice. CONCLUSIONS: Larger well-designed clinical studies are needed to understand the patho-biology of oral cGVHD and determine best treatments for this disease.
OBJECTIVE:Graft-versus-host disease (GVHD) is a leading cause of morbidity and mortality in patients receiving hematopoietic cell transplant. It is estimated that 40-70% of engrafted patients surviving the initial transplant eventually develop chronic GVHD (cGVHD), which can persist for months to years and require long-term management from multiple disciplines. This review describes the oral component of this transplant complication. DESIGN: The search related to GVHD patho-biology, salivary gland disease after hematopoietic cell transplant and treatments for oral GVHD encompassed literature from 1966 through 2008. Searches were limited to the MEDLINE/PubMed database and English language literature in peer-reviewed journals. RESULTS: Our understanding of the patho-biology of oral cGVHD is based on studies of other affected tissues. It is difficult to determine the prevalence and incidence of salivary gland disease after transplant because there is no universally accepted case definition. In general, clinical trials for treatment of oral cGVHD have been too small to make strong recommendations for use in clinical practice. CONCLUSIONS: Larger well-designed clinical studies are needed to understand the patho-biology of oral cGVHD and determine best treatments for this disease.
Authors: Howard M Shulman; David Kleiner; Stephanie J Lee; Thomas Morton; Steven Z Pavletic; Evan Farmer; J Margaret Moresi; Joel Greenson; Anne Janin; Paul J Martin; George McDonald; Mary E D Flowers; Maria Turner; Jane Atkinson; Jay Lefkowitch; M Kay Washington; Victor G Prieto; Stella K Kim; Zsolt Argenyi; A Hafeez Diwan; Asif Rashid; Kim Hiatt; Dan Couriel; Kirk Schultz; Sharon Hymes; Georgia B Vogelsang Journal: Biol Blood Marrow Transplant Date: 2006-01 Impact factor: 5.742
Authors: Matin M Imanguli; Steven Z Pavletic; Jean-Pierre Guadagnini; Jaime S Brahim; Jane C Atkinson Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Endod Date: 2006-02
Authors: Kouhei Yamashita; Mitchell E Horwitz; Akua Kwatemaa; Effie Nomicos; Kathleen Castro; Robert Sokolic; Susan F Foster; Mary Garofalo; Uimook Choi; Mark Ryherd; Margaret R Brown; Susan F Leitman; Alan S Wayne; Daniel H Fowler; Michael R Bishop; Richard W Childs; A John Barrett; Steven Z Pavletic; Harry L Malech Journal: Biol Blood Marrow Transplant Date: 2006-01 Impact factor: 5.742
Authors: Laurie E Harrington; Robin D Hatton; Paul R Mangan; Henrietta Turner; Theresa L Murphy; Kenneth M Murphy; Casey T Weaver Journal: Nat Immunol Date: 2005-10-02 Impact factor: 25.606
Authors: Kathrin Rieger; Christoph Loddenkemper; Jochem Maul; Thomas Fietz; Daniel Wolff; Harald Terpe; Beate Steiner; Erika Berg; Stephan Miehlke; Martin Bornhäuser; Thomas Schneider; Martin Zeitz; Harald Stein; Eckhard Thiel; Rainer Duchmann; Lutz Uharek Journal: Blood Date: 2005-11-08 Impact factor: 22.113
Authors: Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers Journal: Biol Blood Marrow Transplant Date: 2005-12 Impact factor: 5.742
Authors: C W Bassim; H Fassil; J W Mays; D Edwards; K Baird; S M Steinberg; K M Williams; E W Cowen; S A Mitchell; K Cole; T Taylor; D Avila; D Zhang; D Pulanic; L Grkovic; D Fowler; R E Gress; S Z Pavletic Journal: Bone Marrow Transplant Date: 2013-09-02 Impact factor: 5.483
Authors: Leanne K Jackson; Douglas B Johnson; Jeffrey A Sosman; Barbara A Murphy; Joel B Epstein Journal: Support Care Cancer Date: 2014-09-13 Impact factor: 3.603
Authors: C W Bassim; H Fassil; M Dobbin; S M Steinberg; K Baird; K Cole; G Joe; L E Comis; S A Mitchell; L Grkovic; D Edwards; J W Mays; E W Cowen; D Pulanic; K M Williams; R E Gress; S Z Pavletic Journal: Bone Marrow Transplant Date: 2014-07-14 Impact factor: 5.483
Authors: C W Bassim; H Fassil; J W Mays; D Edwards; K Baird; S M Steinberg; E W Cowen; H Naik; M Datiles; P Stratton; R E Gress; S Z Pavletic Journal: J Dent Res Date: 2015-03-04 Impact factor: 6.116
Authors: N Treister; X Chai; B Kurland; S Pavletic; D Weisdorf; J Pidala; J Palmer; P Martin; Y Inamoto; M Arora; M Flowers; D Jacobsohn; M Jagasia; S Arai; S J Lee; C Cutler Journal: Bone Marrow Transplant Date: 2013-01-28 Impact factor: 5.483